{"changeSha256":"87375a49354d836190e842f072762c1dc0d6594ce281fe6139c7570a227dbdf9","changedAt":"2026-11-14","changedFields":[{"after":"A synthetic GHRH analogue that is not FDA-approved. FDA treats CJC-1295 and CJC-1295 with DAC as distinct substances and found only small, short studies in healthy adults.","before":"FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.","field":"Profile summary"},{"after":"FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among substances that may present significant safety risks. CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.","before":"FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.","field":"Evidence note"},{"after":"fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-cjc-1295-briefing-2024, federal-register-2024-24828-d546fa8a5f55, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-cjc-1295-briefing-2024","field":"Cited source records"},{"after":"U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]","before":"U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]","field":"Named organizations"},{"after":"name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-cjc-1295-briefing-2024; evidenceNote: fda-cjc-1295-briefing-2024, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026","before":"name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-cjc-1295-briefing-2024; evidenceNote: fda-cjc-1295-briefing-2024","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/cjc-1295/versions/3/","version":3},"id":"profile:cjc-1295:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added a plain-language reader guide with cited answers, re-checked FDA’s CJC-1295 evaluation and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include CJC-1295.","peptideSlugs":["cjc-1295"],"previousChangeEvent":{"path":"/corrections/v1/profiles/cjc-1295/v2.json","sha256":"b782e4d620158005d1f3cc7182736c883b5d07436f846829a184de687ed7ee04"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/cjc-1295/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"fda-cjc-1295-briefing-2024","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024","url":"https://www.fda.gov/media/183819/download","verifiedAt":"2026-09-15"},{"id":"fda-bulk-peptide-risks","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Certain bulk drug substances for use in compounding that may present significant safety risks","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","verifiedAt":"2026-11-14"},{"id":"hhs-503a-peptide-enforcement-discretion-policy-2026","name":"U.S. Department of Health and Human Services","sourceClass":"A","title":"HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications)","url":"https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"cjc-1295","type":"profile"}}
